Krishna Sarma

Amrita Therapeutics Ltd. develops and commercializes novel drugs for health diseases. The firm engages in dual program of research on both novel peptide-based therapies and development of hybrid therapeutic devices to provide in situ cancer therapy. The company was founded by Ananda M. Chakrabarty and Susan Kling Finston in 2008 and is headquartered in Ahmedabad, India.

Amrita Therapeutics Ltd. develops and commercializes novel drugs for health diseases. The firm engages in dual program of research on both novel peptide-based therapies and development of hybrid therapeutic devices to provide in situ cancer therapy. The company was founded by Ananda M. Chakrabarty and Susan Kling Finston in 2008 and is headquartered in Ahmedabad, India.

Amrita Therapeutics Ltd. develops and commercializes novel drugs for health diseases. The firm engages in dual program of research on both novel peptide-based therapies and development of hybrid therapeutic devices to provide in situ cancer therapy. The company was founded by Ananda M. Chakrabarty and Susan Kling Finston in 2008 and is headquartered in Ahmedabad, India.

Amrita Therapeutics Ltd. develops and commercializes novel drugs for health diseases. The firm engages in dual program of research on both novel peptide-based therapies and development of hybrid therapeutic devices to provide in situ cancer therapy. The company was founded by Ananda M. Chakrabarty and Susan Kling Finston in 2008 and is headquartered in Ahmedabad, India.

Amrita Therapeutics Ltd. develops and commercializes novel drugs for health diseases. The firm engages in dual program of research on both novel peptide-based therapies and development of hybrid therapeutic devices to provide in situ cancer therapy. The company was founded by Ananda M. Chakrabarty and Susan Kling Finston in 2008 and is headquartered in Ahmedabad, India.